Delving into the Latest Updates on R-Pharm Overseas, Inc. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Fusion protein

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3
Neoplasms	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5
Fusion protein	2
Monoclonal antibody	1

Top 5 Target	Count

IL-6(Interleukin-6)	1
TGF-β(Transforming growth factor beta)	1
MEK(STE7 family)	1
IL-1β(Interleukin-1 beta)	1
Opioid receptors	1

Author: Meray, Imad ; Staroverov, Ilya ; Bogin, Vlad ; Rozanov, Denis ; Cremer, Paul C. ; Selezneva, Natalia ; Ponomar, Ekaterina G. ; Mekhriakov, Sergei ; Lonchakova, Oxana ; Pereverzeva, Kristina ; Safarian, Vakhtang ; Popov, Nikolay ; Abbate, Antonio ; Agirov, Murat ; Savelieva, Ekaterina ; Golino, Michele ; Duhanina, Ekaterina ; Buono, Marco Giuseppe Del ; Babaeva, Lala ; Kotova, Anastasia ; Markley, Roshanak ; Fedash, Andrey ; Privalova, Olga ; Mayorov, Vyacheslav ; Zyuryaev, Ilya ; Yakushin, Sergey ; Kalimulin, Denis ; Ivanova, Galina ; Zubova, Ekaterina ; Talasaz, Azita H. ; Marawan, Amr ; Taylor, Angela ; Lavrovsky, Yan ; Pevzner, Dmitry V. ; Grishin, Sergey A. ; Samsonov, Mikhail Yu ; Novosadov, Vladimir ; Osmanova, Samra ; Nilk, Rostislav ; Pisaryuk, Alexandra ; Lapin, Oleg ; Shogenov, Zaur ; Van Tassell, Benjamin ; Kalashnikov, Igor ; Yurkovskiy, Andrey ; Damonte, Juan Ignacio ; Thomas, Georgia ; Turlington, Jeremy S. ; Egorova, Alina N. ; Kornilov, Egor ; Privalov, Dmitry V. ; Pravkina, Ekaterina ; Seleznev, Sergey

01 Jul 2023·Journal of the American College of Cardiology

Treatment of Idiopathic Recurrent Pericarditis With Goflikicept

Article

Author: Maslyanskiy, Alexey L ; Lavrovsky, Yan ; Grishin, Sergey A ; Schedrova, Margarita L ; Gleykina, Ekaterina V ; Egorova, Alina N ; Samsonov, Mikhail Yu ; Abbate, Antonio ; Myachikova, Valentina Yu ; Moiseeva, Olga M ; Vinogradova, Oksana V

BACKGROUNDIdiopathic recurrent pericarditis (IRP) is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis and its recurrence. We created a phase II/III study with a new IL-1 inhibitor-goflikicept in IRP.OBJECTIVESThis study sought to evaluate the efficacy and safety of goflikicept treatment in patients with IRP.METHODSWe conducted a 2-center open-label study of goflikicept in patients with IRP with and without recurrence at time of enrollment. The study consisted of 4 periods: screening, run-in (open-label treatment period), randomized withdrawal, and follow-up. Patients with clinical response to goflikicept in the run-in period were randomized (1:1) to a placebo-controlled withdrawal period, where the time to first pericarditis recurrence (primary endpoint) was evaluated.RESULTSWe enrolled 22 patients, and 20 of these patients were randomized. Reduction of C-reactive protein level accompanied by reduction of chest pain and pericardial effusion compared to baseline was demonstrated during the run-in period. Recurrence of pericarditis occurred in 9 of 10 patients in the placebo group, and there were no recurrence events in goflikicept group within 24 weeks after randomization (P < 0.001). A total of 122 adverse events were reported in 21 patients (95.5%), with no deaths and no new safety signals identified for goflikicept.CONCLUSIONSTreatment with goflikicept prevented recurrences and maintained IRP remission with a favorable risk-benefit ratio. Goflikicept reduced the risk of recurrence compared with placebo. (Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis; NCT04692766).

01 Apr 2017·Journal of Clinical Psychopharmacology

Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial)

Article

Author: Morozova, Margarita ; Burminskiy, Denis ; Lepilkina, Taissia ; Vostokova, Natalia ; Ivaschenko, Alexander ; Rupchev, George ; Potanin, Sergey ; Beniashvili, Allan ; Lavrovsky, Yan

AbstractBackgroundTreating patients who experience residual psychotic symptoms during remission of schizophrenia remains one of the most challenging problems. The mechanisms underlying these symptoms differ from those of acute hallucinations and delusions. 5-HT6 receptor antagonists have been considered promising agents in treatment of residual psychotic symptoms and cognitive dysfunction. The aim of the study was to assess the efficacy of a selective 5-HT6 inhibitor Avisetron in the reduction of residual psychotic symptoms in patients with schizophrenia on stable antipsychotic therapy.MethodsEighty clinically stable outpatient subjects with schizophrenia with residual psychotic symptoms were randomized in a double-blind manner to 6 weeks of Avisetron or placebo at 1:1 ratio. Subjects received 8 mg of Avisetron or placebo on top their stable antipsychotic treatment. Standard clinical scales and cognitive tests were used for endpoint assessment. The primary efficacy endpoint was the mean reduction of total Positive and Negative Syndrome Scale score after 6 weeks of treatment.ResultsNo significant differences in the primary and secondary endpoints were found between the groups. However, based on the subgroup analysis, the significant improvement of total Positive and Negative Syndrome Scale score and residual psychotic symptoms was observed in female patients.ConclusionsIt was a negative study with unexpected benefits of the drug only in females. We hypothesized that the role of patients' sex can impact the treatment response to serotonergic drugs in general. We suggest a possible synergistic interaction between estrogen and Avisetron by means of modulating the effect of estrogens on the serotonergic system. Future studies targeting the sex-related effects of serotonergic drugs are warranted.

100 Deals associated with R-Pharm Overseas, Inc.

Login to view more data

100 Translational Medicine associated with R-Pharm Overseas, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Preclinical

Phase 3 Clinical

1

4

NDA/BLA

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Olokizumab ( IL-6 )	Rheumatoid Arthritis More	NDA/BLA
Odelepran ( Opioid receptors )	Alcoholism More	NDA/BLA
Nemonoxacin Malate ( Bacterial DNA gyrase x Topoisomerase IV )	Infectious Diseases More	NDA/BLA
Imidafenacin ( M1 receptor x M3 receptor )	Pollakisuria More	NDA/BLA
Goflikicept ( IL-1β )	Pericarditis More	Phase 3 Clinical